Literature DB >> 22790269

Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia.

Paola Giordano1, Giuseppe Lassandro, Riccardina Tesse, Stefania Longo, Federica Valente, Anna Rita Cappiello, Antonio Coppola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22790269      PMCID： PMC3557485          DOI： 10.2450/2012.0016-12

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  27 in total

1.  Use of recombinant factor VIIa in inherited platelet disorders.

Authors:  Mohamed Kaleelrahman; Adrian Minford; Liakat Ali Parapia
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

2.  A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa.

Authors:  L Tengborn; B Petruson
Journal:  Thromb Haemost       Date:  1996-06       Impact factor: 5.249

Review 3.  Glanzmann's thrombasthenia: the spectrum of clinical disease.

Authors:  J N George; J P Caen; A T Nurden
Journal:  Blood       Date:  1990-04-01       Impact factor: 22.113

4.  Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia.

Authors:  M C Poon; C Demers; F Jobin; J W Wu
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

Review 5.  Platelet function disorders.

Authors:  A D Shapiro
Journal:  Haemophilia       Date:  2000-07       Impact factor: 4.287

6.  The use of recombinant factor VIIa in children with inherited platelet function disorders.

Authors:  Antonio M Almeida; Kate Khair; Ian Hann; Ri Liesner
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

7.  Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran.

Authors:  G Toogeh; R Sharifian; M Lak; R Safaee; A Artoni; F Peyvandi
Journal:  Am J Hematol       Date:  2004-10       Impact factor: 10.047

8.  Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage.

Authors:  E Furmaniak-Kazmierczak; T D Cooke; R Manuel; A Scudamore; H Hoogendorn; A R Giles; M Nesheim
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 9.  Imaging of musculoskeletal complications of hemophilia.

Authors:  Roger Kerr
Journal:  Semin Musculoskelet Radiol       Date:  2003-06       Impact factor: 1.777

10.  Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.

Authors:  M-C Poon; R D'Oiron; M Von Depka; K Khair; C Négrier; A Karafoulidou; A Huth-Kuehne; M Morfini
Journal:  J Thromb Haemost       Date:  2004-07       Impact factor: 5.824
View more
  2 in total

1.  The expanding role of prophylaxis with recombinant activated factor VII.

Authors:  Annarita Tagliaferri; Massimo Franchini
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

Review 2.  Recombinant activated factor VII in clinical practice: a 2014 update.

Authors:  Massimo Franchini; Silvia Crestani; Francesco Frattini; Cinzia Sissa; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.